Isomorphic Labs raises $5B Series C led by Greenoaks and Sequoia Capital
Greenoaks and Sequoia Capital co-led the round, and Andreessen Horowitz came in as a new investor. Alphabet's GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund, all earlier backers, also invested. The company did not disclose its valuation.
The round follows a $2.1 billion Series B in May, and the money will fund clinical trials for drug candidates that the company says show positive preclinical results in oncology and immunology. Isomorphic has pharma deals with Eli Lilly, Novartis and Johnson & Johnson. Bloomberg reported earlier this month that the lab was in talks to raise at a valuation near $50 billion.
For builders in AI science, the raise shows that investors will finance expensive clinical programs for AI-designed molecules, not only software platforms. Teams selling discovery tools should expect buyers to judge them on clinical progress as well as model performance.